Model choice actually did more work than the tools did ...

Replimune gets third chance at US approval for skin cancer drug Replimune said on Friday it plans to apply a third time for approval of its experimental skin cancer drug in the coming days after ...

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

This project is a proof-of-concept that runs a JavaScript engine inside a web browser by compiling it to WebAssembly. The engine is Goja — a pure-Go implementation of ECMAScript 5.1 — and the ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

Shares of Replimune Group, Inc. (REPL Quick Quote REPL - Free Report) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Sorry to burst your bubble right off the bat, but the show hasn’t even been renewed yet. While Welcome to Derry had a strong start, that number quickly fell off in subsequent episodes. That said, it’s ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Replimune shares fell 54.2% in three months after the FDA issued a CRL against its RP1 BLA in July. The FDA cited shortcomings in the IGNYTE study data but noted no safety concerns with RP1. Replimune ...